Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, open-label, randomized, single-arm clinical trial of oral neflamapimod in amyotrophic lateral sclerosis (ALS) supported by EXPERTS-ALS project

Next Previous
Trial Profile

A multicenter, open-label, randomized, single-arm clinical trial of oral neflamapimod in amyotrophic lateral sclerosis (ALS) supported by EXPERTS-ALS project

Status: Not stated
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neflamapimod (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions

Most Recent Events

  • 17 Mar 2026 According to CervoMed media release, the trial is expected to initiate in the second half of 2026.
  • 05 Mar 2026 New trial record
  • 18 Feb 2026 According to CervoMed media release, this trial is based in UK, and is the first to evaluate neflamapimod in ALS. It is being conducted under the EXPERTS-ALS platform and the first patient is expected to be dosed by end of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top